RetinalGenix Technologies (RetinalGenix Technologies) Debt-to-EBITDA : -0.02 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is RetinalGenix Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RetinalGenix Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.05 Mil. RetinalGenix Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. RetinalGenix Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-2.16 Mil. RetinalGenix Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RetinalGenix Technologies's Debt-to-EBITDA or its related term are showing as below:

RTGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.03 Med: -0.02 Max: -0.01
Current: -0.02

During the past 4 years, the highest Debt-to-EBITDA Ratio of RetinalGenix Technologies was -0.01. The lowest was -0.03. And the median was -0.02.

RTGN's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.23 vs RTGN: -0.02

RetinalGenix Technologies Debt-to-EBITDA Historical Data

The historical data trend for RetinalGenix Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RetinalGenix Technologies Debt-to-EBITDA Chart

RetinalGenix Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.03

-0.01

-0.02

RetinalGenix Technologies Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial									-0.02	-0.02	-0.04	-0.02	-0.02

Competitive Comparison of RetinalGenix Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, RetinalGenix Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RetinalGenix Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RetinalGenix Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RetinalGenix Technologies's Debt-to-EBITDA falls into.

RetinalGenix Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RetinalGenix Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.049	+	0)	/	-2.087
	=	-0.02

RetinalGenix Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.049	+	0)	/	-2.164
	=	-0.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

RetinalGenix Technologies (OTCPK:RTGN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

RetinalGenix Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RetinalGenix Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

RetinalGenix Technologies (RetinalGenix Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RetinalGenix Technologies Inc (OTCPK:RTGN) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 North McDowell Boulevard, Suite 150, Petaluma, CA, USA, 94954

Website

https://www.retinalgenix.com

RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: (1) Retinal Imaging Screening Device (RetinalGenixTM), being designed as a portable, high-resolution retinal imaging Diabetic screening system providing a 200-degree field of view without requiring pupil dilation; and (2) RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7.